Why the form of iron matters
Every iron supplement delivers the same active ingredient: elemental iron. What differs between forms is the chemical structure that surrounds it — which determines how quickly iron is released in the stomach, what concentration of free ions reaches the mucosal surface, and how much oxidative damage results.
The form is not a marketing distinction. It is a chemistry distinction with direct clinical consequences.
Complete comparison of iron supplement forms
| Iron form | Type | GI tolerability | Absorption | Verdict |
|---|---|---|---|---|
| Ferrous bisglycinate | Chelated (amino acid) | Excellent | High (food-stable) | Best for sensitive stomachs |
| Ferrous gluconate | Organic salt | Good | Good | Good tolerated alternative |
| Ferrous fumarate | Organic salt | Moderate | Good — high elemental % | Moderate tolerability |
| Ferrous sulphate | Inorganic salt | Poor | Good (fasted) | High side effect burden |
| Carbonyl iron | Elemental iron | Good | Moderate — slow release | Good tolerability, lower peak absorption |
Why ferrous sulphate causes the most gastric damage
Ferrous sulphate is a simple inorganic salt. When it dissolves in gastric fluid, it dissociates completely into free Fe²⁺ ions and sulphate. The iron is instantly available in its most chemically reactive state — free ferrous ions that immediately catalyse the Fenton reaction, generating hydroxyl radicals that attack the gastric epithelium. There is no buffering. No delay. No moderation of ion concentration. The mucosa receives the full oxidative impact in a short window.
Ferrous sulphate supplementation causes significantly more gastrointestinal side effects than other iron preparations across all major symptom categories — nausea, constipation, and upper abdominal pain — as confirmed by systematic review and meta-analysis of randomised controlled trials.
Why ferrous bisglycinate is gentler
Ferrous bisglycinate is iron chelated to two molecules of the amino acid glycine. The iron is bound within the chelate complex, which must be partially broken down before free iron ions are released. This slows the process in two ways: the chelate complex is more resistant to rapid dissolution in gastric acid than simple inorganic salts, and glycine itself buffers some of the iron's direct mucosal contact during the partial dissolution process.
The result is a lower peak concentration of free iron ions in the gastric environment, and a reduced rate of Fenton reaction catalysis — meaning less hydroxyl radical generation, less lipid peroxidation, and less NF-kB-driven inflammation.
Bisglycinate's absorption is stable in the presence of food. Ferrous sulphate's absorption drops significantly when taken with food. This matters because taking iron with food is the most effective way to reduce gastric side effects — but with sulphate, doing so compromises absorption. Bisglycinate resolves this trade-off: food-stable absorption allows patients to take it with a small meal without sacrificing efficacy.
The case for switching — who most needs it
- No significant GI side effects on current course
- Taking fasted consistently and tolerating well
- Cost is a critical constraint and symptoms are manageable
- Short-term course (under 4 weeks)
- Side effects are preventing course completion
- You have diagnosed or suspected gastritis or H. pylori
- You need to take iron with food (pregnancy, morning dosing)
- GI side effects have caused previous course abandonment
References
- Tolkien Z et al. Ferrous sulfate causes significant gastrointestinal side-effects in adults. PLOS ONE. 2015;10(2):e0117383. PMID 25700159. Systematic review and meta-analysis of RCTs directly comparing GI side effect rates across iron forms — the primary evidence source for the form-tolerability differences described in this article.
- Cancelo-Hidalgo MJ et al. Tolerability of different oral iron supplements. Current Medical Research and Opinion. 2013;29(4):291–303. PMID 23252877. Source of the 38% early discontinuation rate and the tolerability comparison across iron salt forms.
- Friedman AJ et al. Ferrous bisglycinate chelate and polymaltose iron for the treatment of iron deficiency anemia. Journal of the American Association of Gynecologic Laparoscopists. 2011;18(6):e33. PMID 22093373. Clinical comparison of ferrous bisglycinate and other iron forms for efficacy and tolerability — supporting equivalent or better iron repletion with bisglycinate.
This article discusses iron form tolerability differences that are well-established in peer-reviewed literature. The Fenton reaction chemistry is fundamental biochemistry. The clinical comparison data is drawn from systematic reviews and RCTs conducted predominantly in Western and South American populations. Limited direct clinical data on Indian-specific iron form tolerability exists, though the underlying chemistry is not population-specific.